205 related articles for article (PubMed ID: 14567535)
1. Update on Novo Nordisk's clinical trial programme on NovoSeven.
Dejgaard A
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S39-41. PubMed ID: 14567535
[TBL] [Abstract][Full Text] [Related]
2. Ongoing NovoSeven trials.
Erhardtsen E
Intensive Care Med; 2002 Oct; 28 Suppl 2():S248-55. PubMed ID: 12404094
[TBL] [Abstract][Full Text] [Related]
3. Recombinant activated factor VII as a general haemostatic agent: evidence-based efficacy and safety.
Squizzato A; Ageno W
Curr Drug Saf; 2007 May; 2(2):155-61. PubMed ID: 18690962
[TBL] [Abstract][Full Text] [Related]
4. Analysis and results of the recombinant factor VIIa extended-use registry.
Laffan M; O'Connell NM; Perry DJ; Hodgson AJ; O'Shaughnessy D; Smith OP
Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S35-8. PubMed ID: 14567534
[TBL] [Abstract][Full Text] [Related]
5. Recombinant factor VIIa (Novoseven) as a hemostatic agent.
Hedner U
Semin Hematol; 2001 Oct; 38(4 Suppl 12):43-7. PubMed ID: 11735110
[TBL] [Abstract][Full Text] [Related]
6. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
Stanworth SJ; Birchall J; Doree CJ; Hyde C
Cochrane Database Syst Rev; 2007 Apr; (2):CD005011. PubMed ID: 17443565
[TBL] [Abstract][Full Text] [Related]
7. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
Brenner B; Wiis J
Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of recombinant factor VIIa.
Roberts HR; Monroe DM; Hoffman M
Semin Hematol; 2004 Jan; 41(1 Suppl 1):101-8. PubMed ID: 14872430
[TBL] [Abstract][Full Text] [Related]
9. Recombinant factor VIIa (Novoseven) and the safety of treatment.
Roberts HR
Semin Hematol; 2001 Oct; 38(4 Suppl 12):48-50. PubMed ID: 11735111
[TBL] [Abstract][Full Text] [Related]
10. Recombinant factor VIIa in the treatment of bleeding.
Midathada MV; Mehta P; Waner M; Fink LM
Am J Clin Pathol; 2004 Jan; 121(1):124-37. PubMed ID: 14750250
[TBL] [Abstract][Full Text] [Related]
11. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
Cochrane Database Syst Rev; 2011 Feb; (2):CD005011. PubMed ID: 21328270
[TBL] [Abstract][Full Text] [Related]
12. To general haemostasis--the evidence-based route.
Erhardtsen E
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():47-52. PubMed ID: 12214148
[TBL] [Abstract][Full Text] [Related]
13. Recombinant activated factor VII (rFVIIa, NovoSeven).
Agarwal MB; Patnaik M
J Assoc Physicians India; 2005 Aug; 53():717-20. PubMed ID: 16398083
[TBL] [Abstract][Full Text] [Related]
14. The emerging role of recombinant-activated factor VII in neurocritical care.
Fewel ME; Park P
Neurocrit Care; 2004; 1(1):19-29. PubMed ID: 16174895
[TBL] [Abstract][Full Text] [Related]
15. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
16. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review.
Grounds M
Blood Rev; 2003 Sep; 17 Suppl 1():S11-21. PubMed ID: 14697209
[TBL] [Abstract][Full Text] [Related]
17. Immune tolerance induction: a role for recombinant activated factor VII (rFVIIa)?
Brackmann HH; Effenberger W; Hess L; Schwaab R; Oldenburg J
Eur J Haematol Suppl; 1998; 63():18-23. PubMed ID: 9882928
[TBL] [Abstract][Full Text] [Related]
18. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
Weiskopf RB
Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
[TBL] [Abstract][Full Text] [Related]
19. Recombinant activated factor VII in critical bleeding: experience from the Australian and New Zealand Haemostasis Register.
Isbister J; Phillips L; Dunkley S; Jankelowitz G; McNeil J; Cameron P
Intern Med J; 2008 Mar; 38(3):156-65. PubMed ID: 17916172
[TBL] [Abstract][Full Text] [Related]
20. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
Smith OP
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
